ProPhase Labs/PRPH

$4.96

0%
-
1D1W1MYTD1YMAX

About ProPhase Labs

ProPhase Labs, Inc. is a diagnostics, genomics and biotech company. The Company leverages its Clinical Laboratory Improvement Amendments (CLIA) lab services to provide whole genome sequencing and research direct to consumers and build a genomics database to be used for further research. It provides traditional CLIA molecular laboratory services, including coronavirus disease (COVID-19) testing. It also operates Pharmaloz, a contract manufacturing subsidiary, which offers the TK Supplements line of dietary supplements, which are distributed in food, drug, and mass stores. The Company's wholly owned subsidiary ProPhase Diagnostics, Inc, offers a broad array of clinical diagnostic and testing services at its CLIA-certified laboratories including polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19) and Influenza A and Influenza B. It also owns the exclusive rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test.
Ticker
PRPH
Sector
Consumer Non-Cyclicals
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Ted Karkus
Employees
129
Headquarters
New york, United States

ProPhase Labs Metrics

BasicAdvanced
$89.5M
Market cap
-
P/E ratio
-$0.62
EPS
-0.31
Beta
-
Dividend rate

What the Analysts think about ProPhase Labs

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 2 analysts.
212.5% upside
High $20.00
Low $11.00
$4.96
Current price
$15.50
Average price target

ProPhase Labs Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-61.44% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$8.3M
-37.12%
Net income
$-5.1M
50%
Profit margin
-61.44%
138.6%

ProPhase Labs Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 53.85%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.12
$0.03
-$0.20
-$0.30
-
Expected
$0.03
-$0.09
-$0.14
-$0.20
-$0.26
Surprise
-580%
-133.33%
42.86%
53.85%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell ProPhase Labs stock

Buy or sell ProPhase Labs stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing